Reverb Therapeutics, a Vancouver-based biotechnology startup, has successfully raised $12 million in seed financing to accelerate the development of its innovative antibody-based platform, Amplify•R™. The funding round was led by Amplitude Ventures, with additional participation from the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment Corp., and Seido Capital. This investment will support the company's efforts to engineer novel therapies aimed at harnessing cytokine signaling for the treatment of cancer and autoimmune diseases.

Breakthrough in Cytokine-Targeted Therapy

Founded in 2023 by CEO David de Graaf and Chief Science Officer Surjit Dixit, Reverb Therapeutics emerged from Amplitude Ventures' Pre-Amp venture studio program. The company is focused on addressing long-standing challenges in cytokine therapy, such as systemic toxicity, immunogenicity, and manufacturing difficulties. By leveraging bispecific antibody engineering and data-driven modeling, its Amplify•R platform seeks to precisely direct endogenous cytokines to target cells, enhancing immune response while mitigating adverse effects.

Strategic Investment and Board Expansion

As part of the funding round, Amplitude Ventures' Principal Bharat Srinivasa and Partner Jean-François Pariseau will join Reverb Therapeutics' board of directors. Their expertise in biotech investments and strategic growth is expected to contribute significantly to the company's trajectory. The backing from a diverse group of investors underscores strong confidence in Reverb's approach to developing next-generation immune-based therapies.

Advancing the Lead IL-15 Bispecific Program

Reverb's lead program, AMP01, is designed to block a protein that suppresses immune response while simultaneously delivering a cytokine that expands and activates T cells. This dual mechanism enhances the body's ability to combat infections and cancerous cells, offering a promising therapeutic alternative. The funding will enable the company to push AMP01 toward candidate selection and expand its portfolio to include additional cytokine-directed therapies for various diseases.

A Vision for the Future

With preclinical studies already demonstrating the platform's ability to shrink tumors through cytokine redirection, Reverb Therapeutics is well-positioned to make a significant impact in the biotech landscape. The company aims to refine its proprietary approach further, ensuring that its therapies reach clinical development stages with robust safety and efficacy profiles. By advancing its pipeline, Reverb seeks to redefine possibilities in immune-based therapeutics and offer new hope for patients facing cancer and autoimmune disorders.

The successful seed financing marks a critical milestone for Reverb Therapeutics as it continues to innovate in the field of cytokine-targeted therapies. With strong investor backing and a clear vision for development, the company is set to drive meaningful advancements in immune-based treatment strategies. As it moves forward, Reverb remains committed to unlocking the full potential of cytokines in combating complex diseases and transforming patient care.